Table 3 shows that tamoxifen significantly contributed to the progression of fatty liver [hazard ratio (HR): 1.598, 95% confidence interval (CI): 1.173–2.177, P = 0.003] as compared with other treatments modality after adjusting for BMI, progesterone receptor (PR), and FSH. This effect of tamoxifen on fatty liver was consistently meaningful whether or not fatty liver was present at baseline (S1 Table). Here, BRD2 is linked to fatty liver disease.